Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

Clinical and Translational Oncology

Volumn 17, Issue 8, 2015, Pages 604-611

  Aydin, D ^a   Bilici, A ^b   Yavuzer, D ^c   Kefeli, U ^d   Tan, A ^c   Ercelep, O ^a   Mert, A ^a   Yuksel, S ^a   Ozcelik, M ^a   Isik, D ^a   Surmeli, H ^a   Odabasi, H ^a   Aliustaoglu, M ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^c Dr Lutfi Kirdar Education and Research Hospital   (Turkey)

^d KOCAELI UNIVERSITY   (Turkey)

Author keywords

ADAM17; Gastric cancer; Prognosis

Indexed keywords

FLUOROPYRIMIDINE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; TUMOR MARKER; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; STOMACH CANCER; THORAX RADIOGRAPHY; TUMOR INVASION; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; CANCER STAGING; CARCINOMA, SIGNET RING CELL; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADAM PROTEINS; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SIGNET RING CELL; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84937974213     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1283-1     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
3. Blobel CP. ADAMs: key components in EGFR signaling and development. Nat Rev Mol Cell Biol. 2005;6:32–43.
4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Asp Med. 2008;29:258–89.
5. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45(2):146–69.
6. Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140–4.
7. Rose-John S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res. 2013;71:19–22.
8. Shou ZX, Jin X, Zhau ZS. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 2012;256(6):1014–22.
9. Zhang TC, Zhu WG, Huang MD, Fan RH, Chen XF. Prognostic value of ADAM17 in human gastric cancer. Med Oncol. 2012;29(4):2684–90.
10. Edge SB, Byrd DR, Compton CC, et al., editors. American Joint Committee on Cancer Staging Manual. 7th ed. Springer, New York; 2010. p. 117.
11. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer. 1998;1:10–24.
12. Katakowski M, Jiang F, Zheng X, Gutierrez JA, Szalad A, Chopp M. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci. 2009;100:1597–604.
13. Arribas J, Bech-Serra JJ, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev. 2006;25:57–68.
14. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE, Chopp M. ADAM17 Promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Therapy. 2009;8(11):1045–54.
15. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. TACE is required for activation of the EGFR by TGF-alpha in tumors. EMBO J. 2003;22:1114–24.
16. McGowan PM, Ryan BM, Hill AD, McDermott E, O’Higgins N, Duffy MJ. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 2007;13:2335–43.
17. McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, et al. ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 2008;19:1075–81.